Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Treatment of patients with malignant lymphoproliferative diseases in the Russian Federation: analysis of the data from 75 regions

https://doi.org/10.17749/2070-4909.2018.11.4.003-015

Full Text:

Abstract

The aim is to analyze the medical records of patients with malignant lymphoproliferative diseases (LPD) in the Russian Federation in 2016- 2017. Materials and methods. Treating physicians in 75 regions of the Russian Federation were asked to fill the survey questionnaire containing 9 types of malignant LPDs (according to the ICD-10 classification). The questions covered the epidemiology of LPD (prevalence, resistant forms, relapses and mortality), the existence of specialized institutions and beds, the costs of medical care in patients with malignant LPD, and the financial support of pharmacotherapy in these patients during their hospital stay. Results. We found that the most common malignant LPD in 2016-2017 was Hodgkin’s lymphoma (73.5 and 73.4%, respectively). The prevalence of resistant forms and recurrences of malignant LPD over this period accounted for 6.8% of the total patient population. In 2017, the number of patients who died was 7.5% less than that in 2016. There are 815 and 1,763 specialized institutions of the oncology and hematology profiles that provide medical care to children and adult patients, respectively. Among the malignant LPDs, the highest costs of drug therapy in 2016 pertained to lymphosarcoma, and in 2017 – to Hodgkin’s lymphoma. In the system of compulsory health insurance (OMC), the largest spending for both adult and pediatric patients in 2016 and 2017 was accounted for Hodgkin’s lymphoma; a similar result was obtained for the cost of therapy based on high-tech medical care. Conclusion. In 2017, the total number of patients with malignant LPD in the Russian Federation increased by 2.65% as compared to 2016, while the proportion of primary LPD decreased by 1.2%. In 2017, the total costs of drug supply in patients with malignant LPD in the RF increased by 55.35% as compared with 2016.

About the Authors

G. R. Hachatryan
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation; Research Financial Institution of the Ministry of Finance of the Russian Federation; Russian Presidential Academy of National Economy and Public Administration
Russian Federation

Georgii R. Khachatryan – Acting Director, Department of Methodological Support of Comprehensive HTA, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation; Researcher at the Laboratory for HTA, Institute of Applied Economic Research of the Presidential Academy; Junior Researcher at the Center for Healthcare Funding, Financial Research Institute;

10-5 Khokhlovskii pereulok, Moscow 109028;

3-2 Nastasyinsky pereulok, Moscow 127006;

82 Vernadskogo prospect, Moscow 119571

 



T. S. Teptsova
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation; Sechenov First Moscow State Medical University
Russian Federation

Tatyana S. Teptsova – Leading Specialist, Department of Methodological Support of Comprehensive HTA, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation; Post-graduate Student at the Department of Pharmacology, Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, Ministry of Healthcare of the Russian Federation;

10-5 Khokhlovskii pereulok, Moscow 109028;

8-2 Trubetskaya Str., Moscow 119048



V. A. Lemeshko
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation; Sechenov First Moscow State Medical University
Russian Federation

Valeriya A. Lemeshko – Leading Specialist, Department of Methodological Support of Comprehensive HTA, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation; Post-graduate Student at the Department of Pharmacology, Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, Ministry of Healthcare of the Russian Federation;

10-5 Khokhlovskii pereulok, Moscow 109028;

8-2 Trubetskaya Str., Moscow 119048



N. Z. Musina
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation; Research Financial Institution of the Ministry of Finance of the Russian Federation; Sechenov First Moscow State Medical University
Russian Federation

Nuriya Z. Musina – PhD, Associate Professor at the Department of Pharmacology, Faculty of Pharmacy, Sechenov First Moscow State Medical University; Head of the Development and Communications Department, Center of Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation, Senior Researcher at the Center for Healthcare Funding, Financial Research Institute;

Researcher ID: C-8075-2018;

10-5 Khokhlovskii pereulok, Moscow 109028;

3-2 Nastasyinsky pereulok, Moscow 127006;

8-2 Trubetskaya Str., Moscow 119048



References

1. Vel’sher L. Z., Matyakin E. G., Dudickaya T. K., Polyakov B. I. Oncology: a textbook for universities. 2009. 512 s. (in Russian).

2. Swerdlow S. H., Campo E., Harris N. L., Jaffe E. S., Pileri S., Stein H. et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008: 312-6.

3. Zeppa P. et al. Immunodeficiency-Associated Lymphoproliferative Disorders. Lymph Node FNC. karger Publishers. 2018; 23: 77-80.

4. Pina-Oviedo S., Miranda R. N., Medeiros L. J. Cancer Therapyassociated Lymphoproliferative Disorders. The American journal of surgical pathology. 2018; 42 (1): 116-129.

5. Kaprin A. D., Starinskij V. V., Petrova G. V. Malignant neoplasms in Russia in 2016 (morbidity and mortality). Moscow. 2018; 250 s. (in Russian).

6. Kaprin A. D., Starinskij V. V., Petrova G. V. The state of cancer care for the population of Russia in 2017. Moscow. 2018; 236 s. (in Russian).

7. Xachatryan G. R., Fedyaev D. V., Avksentyeva M. V., Dombrovskij V. S. Cost-effectiveness analysis of brentuximab vedotin in adults with relapsed or refractory Hodgkin’s lymphoma. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern pharmacoeconomics and pharmacoepidemiology. 2016; 9 (1): 3-14(in Russian). https://doi.org/10.17749/2070-4909.2016.9.1.003-014.

8. Myakova N. V., Maschan A. A., Rumyancev A. G. Federal’nye klinicheskie rekomendacii po diagnostike i lecheniyu limfomy Xodzhkina (limfogranulematoz). Rossijskij zhurnal detskoj gematologii i onkologii. 2015; 4: 79-90 (in Russian).

9. Englund A. et al. Hodgkin lymphoma in children, adolescents and young adults–a comparative study of clinical presentation and treatment outcome. Acta Oncologica. 2018; 57 (2): 276-282.

10. Alekseev S. M. et al. Modern therapy for relapses and resistant forms of Hodgkin’s lymphoma. Voprosy onkologii. 2018; 64 (3): 419-428 (in Russian).

11. Baryax E. A. Lechenie recidivov i rezistentnyx form limfomy Xodzhkina. Onkogematologiya. 2017; 2: 8-13.

12. Filatova L. V. et al. Risk-adapted strategies for the treatment of Hodgkin’s lymphoma. Voprosy onkologii. 2016; 62 (2): 330-339 (in Russian).

13. Glimelius I., Diepstra A. Novel treatment concepts in Hodgkin lymphoma. Journal of internal medicine. 2017; 281 (3): 247-260.

14. Federal State Statistics Service [Electronic resource]. URL: http://www.gks.ru/. Accessed: 13.07.2018 (in Russian).

15. Ignatyeva V. I., Avksentyeva M. V. Analysis of the methodological features of research on the socio-economic burden of diseases in the Russian Federation as part of the development of a standard methodology for analyzing the cost of the disease in order to use it in the evaluation of health technologies. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern pharmacoeconomics and pharmacoepidemiology. 2014; 7 (3): 3-11 (in Russian).


For citation:


Hachatryan G.R., Teptsova T.S., Lemeshko V.A., Musina N.Z. Treatment of patients with malignant lymphoproliferative diseases in the Russian Federation: analysis of the data from 75 regions. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2018;11(4):3-15. (In Russ.) https://doi.org/10.17749/2070-4909.2018.11.4.003-015

Views: 134


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)